Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review
•Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share common disease pathways given the higher prevalence of NAFLD in PD patients.•Cytokines and metabolic syndrome are possibly links between the two diseases.•Identifying targets in these common disease pathways coul...
Gespeichert in:
| Veröffentlicht in: | Seminars in arthritis and rheumatism 2023-04, Vol.59, p.152165-152165, Article 152165 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 152165 |
|---|---|
| container_issue | |
| container_start_page | 152165 |
| container_title | Seminars in arthritis and rheumatism |
| container_volume | 59 |
| creator | Torosian, Kelly Lal, Esha Kavanaugh, Arthur Loomba, Rohit Ajmera, Veeral Guma, Monica |
| description | •Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share common disease pathways given the higher prevalence of NAFLD in PD patients.•Cytokines and metabolic syndrome are possibly links between the two diseases.•Identifying targets in these common disease pathways could help guide research into drug targets of therapeutics that can treat both disease states simultaneously.•Further studies investigating the impact of biologics on NAFLD and NAFLD therapeutics on PD are needed.
Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share disease pathways given the numerous inflammatory pathways involved in both diseases and a higher prevalence of NAFLD in PD patients. Metabolic syndrome and obesity are a key link between the two diseases, but even when controlling for this, associations between both diseases are still seen. Therapeutics that impact metabolic or inflammatory pathways may be impactful in both PD and NAFLD. In this review, we describe common inflammatory pathways contributing to both PD and NAFLD and critically review the potential impact of treatments for and on both diseases.
[Display omitted] |
| doi_str_mv | 10.1016/j.semarthrit.2023.152165 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9992353</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0049017223000057</els_id><sourcerecordid>2771333504</sourcerecordid><originalsourceid>FETCH-LOGICAL-c479t-1c2b267edb77fca766d2dd2448ffcd4540a287356a9b94d841642a8b663e5d2e3</originalsourceid><addsrcrecordid>eNqFkc1OGzEURq2qqKSBV6hmyWZS_4093iBRVGglJBCiUneWx77DOJqMU9tJxdvjKDTQFSsv7rnftb6DUEXwgmAivi4XCVYm5iH6vKCYsgVpKBHNBzQjDaN1K8Tvj2iGMVc1JpIeo88pLTEmRGD5CR0zIQut1Azd36UQvcneVs4nMAkqM7lqClNtRhuGMJZJb3J-qka_hXig0mAiuGpt8hAeYYLkUxVh6-HvCTrqzZjg9OWdo19X3x8uf9Q3t9c_Ly9uasulyjWxtKNCguuk7K2RQjjqHOW87XvreMOxoa1kjTCqU9y1nAhOTdsJwaBxFNgcne9z15tuBc7ClKMZ9Tr6Us2TDsbr_yeTH_Rj2GqlFGUNKwFnLwEx_NlAynrlk4VxNBOETdJUSsIYazAvaLtHbQwpRegPZwjWOyV6qV-V6J0SvVdSVr-8_eZh8Z-DAnzbA1DKKgVGnayHyYLzEWzWLvj3rzwDZrKlJw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2771333504</pqid></control><display><type>article</type><title>Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review</title><source>MEDLINE</source><source>Access via ScienceDirect (Elsevier)</source><creator>Torosian, Kelly ; Lal, Esha ; Kavanaugh, Arthur ; Loomba, Rohit ; Ajmera, Veeral ; Guma, Monica</creator><creatorcontrib>Torosian, Kelly ; Lal, Esha ; Kavanaugh, Arthur ; Loomba, Rohit ; Ajmera, Veeral ; Guma, Monica</creatorcontrib><description>•Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share common disease pathways given the higher prevalence of NAFLD in PD patients.•Cytokines and metabolic syndrome are possibly links between the two diseases.•Identifying targets in these common disease pathways could help guide research into drug targets of therapeutics that can treat both disease states simultaneously.•Further studies investigating the impact of biologics on NAFLD and NAFLD therapeutics on PD are needed.
Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share disease pathways given the numerous inflammatory pathways involved in both diseases and a higher prevalence of NAFLD in PD patients. Metabolic syndrome and obesity are a key link between the two diseases, but even when controlling for this, associations between both diseases are still seen. Therapeutics that impact metabolic or inflammatory pathways may be impactful in both PD and NAFLD. In this review, we describe common inflammatory pathways contributing to both PD and NAFLD and critically review the potential impact of treatments for and on both diseases.
[Display omitted]</description><identifier>ISSN: 0049-0172</identifier><identifier>EISSN: 1532-866X</identifier><identifier>DOI: 10.1016/j.semarthrit.2023.152165</identifier><identifier>PMID: 36716599</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Humans ; Inflammatory pathways ; Insulin resistance ; Metabolic Syndrome - complications ; Non-alcoholic Fatty Liver Disease ; Obesity - complications ; Pathogenesis ; Psoriatic disease</subject><ispartof>Seminars in arthritis and rheumatism, 2023-04, Vol.59, p.152165-152165, Article 152165</ispartof><rights>2023 Elsevier Inc.</rights><rights>Copyright © 2023 Elsevier Inc. All rights reserved.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c479t-1c2b267edb77fca766d2dd2448ffcd4540a287356a9b94d841642a8b663e5d2e3</citedby><cites>FETCH-LOGICAL-c479t-1c2b267edb77fca766d2dd2448ffcd4540a287356a9b94d841642a8b663e5d2e3</cites><orcidid>0000-0003-1951-9411 ; 0000-0001-8691-0598</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.semarthrit.2023.152165$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>230,315,782,786,887,3552,27931,27932,46002</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36716599$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Torosian, Kelly</creatorcontrib><creatorcontrib>Lal, Esha</creatorcontrib><creatorcontrib>Kavanaugh, Arthur</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Ajmera, Veeral</creatorcontrib><creatorcontrib>Guma, Monica</creatorcontrib><title>Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review</title><title>Seminars in arthritis and rheumatism</title><addtitle>Semin Arthritis Rheum</addtitle><description>•Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share common disease pathways given the higher prevalence of NAFLD in PD patients.•Cytokines and metabolic syndrome are possibly links between the two diseases.•Identifying targets in these common disease pathways could help guide research into drug targets of therapeutics that can treat both disease states simultaneously.•Further studies investigating the impact of biologics on NAFLD and NAFLD therapeutics on PD are needed.
Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share disease pathways given the numerous inflammatory pathways involved in both diseases and a higher prevalence of NAFLD in PD patients. Metabolic syndrome and obesity are a key link between the two diseases, but even when controlling for this, associations between both diseases are still seen. Therapeutics that impact metabolic or inflammatory pathways may be impactful in both PD and NAFLD. In this review, we describe common inflammatory pathways contributing to both PD and NAFLD and critically review the potential impact of treatments for and on both diseases.
[Display omitted]</description><subject>Humans</subject><subject>Inflammatory pathways</subject><subject>Insulin resistance</subject><subject>Metabolic Syndrome - complications</subject><subject>Non-alcoholic Fatty Liver Disease</subject><subject>Obesity - complications</subject><subject>Pathogenesis</subject><subject>Psoriatic disease</subject><issn>0049-0172</issn><issn>1532-866X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkc1OGzEURq2qqKSBV6hmyWZS_4093iBRVGglJBCiUneWx77DOJqMU9tJxdvjKDTQFSsv7rnftb6DUEXwgmAivi4XCVYm5iH6vKCYsgVpKBHNBzQjDaN1K8Tvj2iGMVc1JpIeo88pLTEmRGD5CR0zIQut1Azd36UQvcneVs4nMAkqM7lqClNtRhuGMJZJb3J-qka_hXig0mAiuGpt8hAeYYLkUxVh6-HvCTrqzZjg9OWdo19X3x8uf9Q3t9c_Ly9uasulyjWxtKNCguuk7K2RQjjqHOW87XvreMOxoa1kjTCqU9y1nAhOTdsJwaBxFNgcne9z15tuBc7ClKMZ9Tr6Us2TDsbr_yeTH_Rj2GqlFGUNKwFnLwEx_NlAynrlk4VxNBOETdJUSsIYazAvaLtHbQwpRegPZwjWOyV6qV-V6J0SvVdSVr-8_eZh8Z-DAnzbA1DKKgVGnayHyYLzEWzWLvj3rzwDZrKlJw</recordid><startdate>20230401</startdate><enddate>20230401</enddate><creator>Torosian, Kelly</creator><creator>Lal, Esha</creator><creator>Kavanaugh, Arthur</creator><creator>Loomba, Rohit</creator><creator>Ajmera, Veeral</creator><creator>Guma, Monica</creator><general>Elsevier Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0003-1951-9411</orcidid><orcidid>https://orcid.org/0000-0001-8691-0598</orcidid></search><sort><creationdate>20230401</creationdate><title>Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review</title><author>Torosian, Kelly ; Lal, Esha ; Kavanaugh, Arthur ; Loomba, Rohit ; Ajmera, Veeral ; Guma, Monica</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c479t-1c2b267edb77fca766d2dd2448ffcd4540a287356a9b94d841642a8b663e5d2e3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Humans</topic><topic>Inflammatory pathways</topic><topic>Insulin resistance</topic><topic>Metabolic Syndrome - complications</topic><topic>Non-alcoholic Fatty Liver Disease</topic><topic>Obesity - complications</topic><topic>Pathogenesis</topic><topic>Psoriatic disease</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Torosian, Kelly</creatorcontrib><creatorcontrib>Lal, Esha</creatorcontrib><creatorcontrib>Kavanaugh, Arthur</creatorcontrib><creatorcontrib>Loomba, Rohit</creatorcontrib><creatorcontrib>Ajmera, Veeral</creatorcontrib><creatorcontrib>Guma, Monica</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Seminars in arthritis and rheumatism</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Torosian, Kelly</au><au>Lal, Esha</au><au>Kavanaugh, Arthur</au><au>Loomba, Rohit</au><au>Ajmera, Veeral</au><au>Guma, Monica</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review</atitle><jtitle>Seminars in arthritis and rheumatism</jtitle><addtitle>Semin Arthritis Rheum</addtitle><date>2023-04-01</date><risdate>2023</risdate><volume>59</volume><spage>152165</spage><epage>152165</epage><pages>152165-152165</pages><artnum>152165</artnum><issn>0049-0172</issn><eissn>1532-866X</eissn><abstract>•Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share common disease pathways given the higher prevalence of NAFLD in PD patients.•Cytokines and metabolic syndrome are possibly links between the two diseases.•Identifying targets in these common disease pathways could help guide research into drug targets of therapeutics that can treat both disease states simultaneously.•Further studies investigating the impact of biologics on NAFLD and NAFLD therapeutics on PD are needed.
Psoriatic disease (PD) and non-alcoholic fatty liver disease (NAFLD) potentially share disease pathways given the numerous inflammatory pathways involved in both diseases and a higher prevalence of NAFLD in PD patients. Metabolic syndrome and obesity are a key link between the two diseases, but even when controlling for this, associations between both diseases are still seen. Therapeutics that impact metabolic or inflammatory pathways may be impactful in both PD and NAFLD. In this review, we describe common inflammatory pathways contributing to both PD and NAFLD and critically review the potential impact of treatments for and on both diseases.
[Display omitted]</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>36716599</pmid><doi>10.1016/j.semarthrit.2023.152165</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0003-1951-9411</orcidid><orcidid>https://orcid.org/0000-0001-8691-0598</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0049-0172 |
| ispartof | Seminars in arthritis and rheumatism, 2023-04, Vol.59, p.152165-152165, Article 152165 |
| issn | 0049-0172 1532-866X |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9992353 |
| source | MEDLINE; Access via ScienceDirect (Elsevier) |
| subjects | Humans Inflammatory pathways Insulin resistance Metabolic Syndrome - complications Non-alcoholic Fatty Liver Disease Obesity - complications Pathogenesis Psoriatic disease |
| title | Psoriatic disease and non-alcoholic fatty liver disease shared pathogenesis review |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-04T17%3A45%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Psoriatic%20disease%20and%20non-alcoholic%20fatty%20liver%20disease%20shared%20pathogenesis%20review&rft.jtitle=Seminars%20in%20arthritis%20and%20rheumatism&rft.au=Torosian,%20Kelly&rft.date=2023-04-01&rft.volume=59&rft.spage=152165&rft.epage=152165&rft.pages=152165-152165&rft.artnum=152165&rft.issn=0049-0172&rft.eissn=1532-866X&rft_id=info:doi/10.1016/j.semarthrit.2023.152165&rft_dat=%3Cproquest_pubme%3E2771333504%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2771333504&rft_id=info:pmid/36716599&rft_els_id=S0049017223000057&rfr_iscdi=true |